...
首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A key step towards personalized therapeutics
【24h】

Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A key step towards personalized therapeutics

机译:使用UPLC-MS / MS测定儿科癌症患者血浆中伏立康唑和共施用药物:朝着个性化治疗方法的关键步骤

获取原文
获取原文并翻译 | 示例
           

摘要

Untreated invasive aspergillosis results in high mortality rate in pediatric cancer patients. Voriconazole (VORI), the first line of treatment, requires strict dose monitoring because of its narrow therapeutic index and individual variation in plasma concentration levels. Commonly co-administered drugs; either Esomeprazole (ESO) or Ondansetron (OND) have reported drug-drug interaction with VORI that should adversely alter therapeutic outcomes of the latter. Although VORI, ESO and OND are co-administered to pediatric cancer patients, the combined effect of ESO and OND on the plasma concentration levels of VORI has not been fully explored. In this study, an accurate, reliable and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated for simultaneous determination of VORI, ESO, and OND in ultra-low sample volumes (25 mu L) of plasma of pediatric cancer patients. Based on the physicochemical properties of the studied drugs and internal standard, liquid-liquid extraction was successfully adopted with methyl t-butyl ether. Consistent and reproducible recovery of the three drugs and the internal standard were calculated using plasma and matrix matched samples (RE% 72.97%, RSD 8.29%). Chromatographic separation was carried out using UPLC with C18 column and a mobile phase of acetonitrile:water:methanol (70:25:5 V/V/V) at 0.3mL/min. Mass spectrometric determination at positive electrospray ionization in the MRM mode was employed. The analysis was achieved within 4 min over a linear concentration range of 1.00-200.00 ng/mL for the three drugs. The assay validity was assessed as per the Food and Drug Administration guidelines for bioanalytical method validation, and satisfactory results were obtained. The accuracy and precision were within the acceptable limits for the three drugs in both quality control and incurred plasma samples. Matrix effect and process efficiency were investigated in neat solvent, post-extraction
机译:未经治疗的侵袭性曲柄导致儿科癌症患者的死亡率很高。由于其狭窄的治疗指数和血浆浓度水平的个体变异,葡血酮(Vori)需要严格的剂量监测需要严格的剂量监测。通常共同施用药物; eSomeprazole(ESO)或ondansetron(ond)报告了与vori的药物 - 药物相互作用,这些vori应该不利地改变后者的治疗结果。虽然Vori,ESO和OND与儿科癌症患者共同施用,但ESO和OND对Vori等血浆浓度水平的综合作用尚未得到充分探索。在该研究中,开发并验证了精确,可靠和敏感的液相色谱 - 串联质谱(LC-MS / MS)测定以同时测定超低样品体积(25μl)中的vori,ESO和OND儿科癌症患者等离子体。基于所研究的药物和内标物质化学性质,用甲基叔丁醚成功采用液 - 液萃取。使用血浆和基质匹配样品计算三种药物和内标的一致性和可重复的恢复(Re%& 72.97%,RSD <8.29%)。使用UPLC用C18柱和乙腈的流动相进行色谱分离:水:甲醇(70:25:5V / v),0.3ml / min。采用MRM模式下正电喷雾电离的质谱法测定。对于三种药物的线性浓度范围为1.00-200.00ng / ml的线性浓度范围内达到分析。根据生物分析方法验证的食品和药物管理指南评估测定有效性,并获得令人满意的结果。准确性和精度在质量控制和癌等离子体样本中的三种药物中的可接受限度内。在整齐的溶剂中研究了基质效应和工艺效率,提取后

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号